Meanwhile, expression of markers regarding differentiation and activation of osteoclasts, including C‐fos, Acp5, Ctsk, Nfat‐c1, and Dc‐stamp, were significantly increased in CM‐HCC/RNF219‐treated osteoclasts but decreased in response totreatment with the LGALS3‐neutralizing antibody (Figure S3G, Supporting Information). The gene discussed is ACP5; the disease is hepatocellular carcinoma.